Business profile & competitive position
Johnson & Johnson is a healthcare holding company whose subsidiaries employ roughly 138,200 full-time-equivalent workers worldwide and focus on the research, development, manufacture, and sale of healthcare products. The company reports through two segments: Innovative Medicine, which sells prescription therapeutics in Oncology, Immunology, Neuroscience, Pulmonary Hypertension, Infectious Diseases, and Cardiovascular and Metabolism; and MedTech, which makes devices used in cardiovascular, orthopaedic, surgery, and vision procedures. Products reach retailers, wholesalers, distributors, hospitals, eye-care professionals, and healthcare professionals in virtually all countries.
The financial profile supports the idea of a durable franchise. A 16.2% net margin and 19.6% ROE point to pricing power, efficient capital deployment, and scale advantages that are better than what most industries can sustain. Those returns are consistent with a drug-manufacturer model built around patented biologics and high-margin devices. Revenue concentration is real, though: in 2025, DARZALEX/DARZALEX FASPRO accounted for roughly 15.0% of total revenues, STELARA for about 6.5%, and TREMFYA for about 5.5%. That concentration means the moat is product-cycle dependent, especially as biosimilars to STELARA continue to roll out.
Financial posture
JNJ currently carries a $641.1 billion market capitalization and trades at a 40.4 P/E ratio. The multiple is well above what a slow-growth industrial would command, suggesting the market is paying a premium for the stability of healthcare cash flows and the company’s brand-level diversification. Profitability remains robust: 16.2% net margin and 19.6% ROE confirm that capital is still being reinvested at high returns.
The stock also has a beta of 0.23, which implies very low correlation with broad equity-market swings. That defensive characteristic often accompanies consumer-staples-like revenue streams, and it fits a healthcare conglomerate with recurring device sales and long-duration pharmaceutical franchises. At the same time, a P/E near 40 leaves limited valuation cushion if earnings growth or guidance surprises to the downside.
Strategic priorities & outlook
According to the company’s most recent 10-K filing, the clearest operational priority is completing the planned separation of the Orthopaedics business, announced in October 2025, with a targeted completion within 18 to 24 months. That transaction would reshape the MedTech footprint and leave JNJ more focused on higher-growth, higher-margin pharmaceutical and remaining device markets.
Beyond portfolio restructuring, management emphasizes human capital as a strategic asset. The filing highlights a three-part talent strategy—attracting, developing, and retaining top talent while empowering and inspiring employees—backed by a Credo-based culture focused on innovation, health, well-being, safety, inclusion, and belonging. Programs such as J&J Learn and the annual Global Learning Day are framed as tools to build a talent pipeline that can support long-range R&D and commercial execution. The message is that JNJ treats its workforce and culture as part of the moat, not only patents and products.
Macro & geopolitical exposure
As a Healthcare / Drug Manufacturers - General company, JNJ is exposed to the standard macro and policy levers that affect big pharma and medical devices. Regulatory risk is front and center: approvals, label expansions, and manufacturing inspections by the FDA and EMA directly affect revenue timelines. Pricing pressure is another industry-wide headwind, including foreign government reimbursement negotiations and U.S. policy debates around drug costs.
Currency risk matters because products are sold “in virtually all countries of the world,” so a stronger dollar can compress reported international revenue. Trade policy and tariffs can affect both MedTech supply chains and device demand. Patent cliffs and biosimilar competition—already flagged for STELARA—are persistent themes for the industry. Finally, geopolitical tensions in key markets such as China or Europe can alter regulatory timelines, pricing, and market access for both pharmaceuticals and devices.
Recent developments
On October 26, 2026, four headlines featured JNJ across financial media. GuruFocus reported that “Johnson & Johnson Reveals Striking Cancer Trial Results,” a concrete catalyst in the oncology bucket that drives a large share of revenue. The same day, 247wallst.com included JNJ in a list of “2 Safe S&P 500 Dividend Stocks Boomers Can Buy and Hold Forever,” reinforcing the defensive, income-oriented narrative. MarketBeat mentioned JNJ among “5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps,” while Fool.com compared the iShares Domestic IHE and VanEck Global PPH pharmaceutical ETFs. Together, the coverage tilts toward JNJ as a high-quality, large-cap healthcare name with both dividend appeal and pipeline optionality.
Earnings behavior & post-earnings drift
JNJ has a strong recent earnings record. Over the last eight reported quarters, the company has beaten the consensus estimate seven times and matched it once, producing an average earnings surprise of 2.5%. The stock has also shown a positive post-earnings drift: the average 5-day price move after earnings across those quarters is +1.61%, classified as an “up” drift.
The most recent four reports illustrate how consistent the beats have been, even if day-one reactions vary. On October 13, 2026, JNJ reported EPS of $2.59 against an estimate of $2.52 for a 2.8% surprise; the stock rose 2.13% the next day and 4.32% over the following five days. On July 15, 2026, the company delivered $2.90 versus $2.85, a 1.8% surprise, with a +1.19% next-day move and a +3.49% five-day drift. The April 14, 2026 quarter was a narrower beat—$2.70 versus $2.68, or 0.7%—and the market sold it -0.6% the next day and -5.81% over five days. The January 21, 2026 report was exactly in line at $2.46 versus $2.46, yet the stock still drifted +4.45% over the next five days. JNJ is scheduled to report next on January 20, 2027, before the open, with the current consensus EPS estimate at $2.91.
Frequently Asked Questions
What are Johnson & Johnson’s main business segments?
JNJ operates through Innovative Medicine, which focuses on prescription therapeutics such as oncology and immunology, and MedTech, which makes devices used in cardiovascular, orthopaedic, surgery, and vision procedures.
How has JNJ performed versus earnings estimates lately?
Over the last eight reported quarters, JNJ has beaten the consensus seven times and matched it once, with an average earnings surprise of 2.5% and an average five-day post-earnings drift of +1.61%.
What major strategic change is JNJ pursuing?
The company’s most recent 10-K says it is working to complete the separation of its Orthopaedics business, announced in October 2025, within 18 to 24 months of that announcement.
For a deeper look at how institutions are weighing JNJ’s valuation, pipeline, and upcoming earnings event, review the full institutional verdict on the ticker page.
| Reported | Actual | Estimate | Surprise | 1D Move | 5D Move |
|---|---|---|---|---|---|
| 2026-10-13 | $2.59 | $2.52 | +2.8% | +2.13% | +4.32% |
| 2026-07-15 | $2.9 | $2.85 | +1.8% | +1.19% | +3.49% |
| 2026-04-14 | $2.7 | $2.68 | +0.7% | -0.6% | -5.81% |
| 2026-01-21 | $2.46 | $2.46 | 0% | +0.22% | +4.45% |
| 2025-10-14 | $2.8 | $2.76 | +1.4% | - | - |
| 2025-07-16 | $2.77 | $2.68 | +3.4% | - | - |
Previous JNJ editions
Get the institutional verdict on JNJ
Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.
Read the JNJ verdict at Gamma QCVerify authenticity
Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.